Exercise performance and recovery is the main area connected here, and any felt benefit should be read together with the human evidence base.
Some human supplement-context evidence is present and directly informs the score.
Representative tier calculated from paper evidence that passed the collection audit.
The representative ingredient tier is calculated from these target-level evidence groups.
10 new papers were added in this period. No new risk signal was identified.
Standalone side-effect signals and combination cautions are listed separately.
No standalone side-effect or combination signal is currently clear enough to show from the collected papers. This does not mean there is no concern.
Paper IDs and full lists are private. Only study types and summaries are shown.
There is compelling evidence from preclinical studies that l-carnitine and ALCAR can improve energy status, decrease oxidative stress and prevent subsequent cell death in models of adult, neonatal and pediatric brain injury.
[Abstract]: Significance Identifying biological targets in major depressive disorder (MDD) is a critical step for development of effective mechanism-based medications. The epigenetic agent acetyl-l-carnitine (LAC) has rapid and enduring antidepressant-like eff
It is demonstrated that l-carnitine alleviates muscle injury and reduces markers of cellular damage and free radical formation accompanied by attenuation of muscle soreness, thereby reducing hypoxia-induced cellular and biochemical disruptions.
LC supplementation at a dose of 1000 mg/d was associated with a significant reduction in oxidative stress and an increase in antioxidant enzymes activities in CAD patients, which might benefit from using LC supplements to increase their anti-oxidation capacity
Prolonged LC supplementation in specific conditions may affect physical performance and LC supplementation elevates fasting plasma TMAO, compound supposed to be pro-atherogenic, which was not associated with modification of determined inflammatory nor oxidativ
The effects of ALC on the gut–liver–brain axis seem to identify the category of patients in which the new insights contribute most to the mechanisms of action of A LC, likely being the liver metabolism and the improvement of hepatic detoxifying mechanisms the